TCTR20210514007
Recruiting
Not Applicable
Treatment outcome in elderly patients with acute myeloid leukemia at Siriraj Hospital
Siriraj Hospital Mahidol University0 sites400 target enrollmentMay 14, 2021
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- The patients 60 years and older who were diagnosed and know to have acute myeloid leukemia.
- Sponsor
- Siriraj Hospital Mahidol University
- Enrollment
- 400
- Status
- Recruiting
- Last Updated
- last year
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\. The patients was diagnosed with acute myeloid leukemia. Diagnosed from 1 January 2009 to 31 July 2020\.
- •2\.The patients 60 years and older.
Exclusion Criteria
- •1\.The patient was diagnosed with acute promyelocytic leukemia with PML\-RARA.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Not Applicable
The prognosis of older patients treated about the chronic hepatitis C in the North area of Kyoto, JapaChronic Hepatitis CJPRN-UMIN000027801Kyoto prefectural university of medicine150
Completed
Not Applicable
Investigational study for elderly acute myelocytic leukemiaacute myelocytic leukemiaJPRN-C000000224Japan Adult Leukemia Study Group288
Active, not recruiting
Phase 1
The AML18 Trial is an intensive chemotherapy trial for patients primarily over the age of 60 with AML and High Risk Myelodysplastic disease. This randomised, up to 2000 patient trial will evaluate the effect of adding novel treatment combinations to standard chemotherapy.Acute Myeloid LeukaemiaHigh Risk Myelodysplastic SyndromeMedDRA version: 20.0Level: SOCClassification code 10005329Term: Blood and lymphatic system disordersSystem Organ Class: 10005329 - Blood and lymphatic system disordersTherapeutic area: Diseases [C] - Blood and lymphatic diseases [C15]EUCTR2013-002730-21-GBCardiff University2,000
Active, not recruiting
Phase 1
The AML18 Trial is an intensive chemotherapy trial for patients primarily over the age of 60 with AML and High Risk Myelodysplastic disease. This randomised, up to 2000 patient trial will evaluate the effect of adding novel treatment combinations to standard chemotherapy.Acute Myeloid LeukaemiaHigh Risk Myelodysplastic SyndromeMedDRA version: 20.0Level: SOCClassification code 10005329Term: Blood and lymphatic system disordersSystem Organ Class: 10005329 - Blood and lymphatic system disordersTherapeutic area: Diseases [C] - Blood and lymphatic diseases [C15]EUCTR2013-002730-21-DKCardiff University2,000
Completed
Not Applicable
The prognosis of the super elderly patients with acute coronary syndrome who underwent percutaneous coronary intervention : A retrospective cohort studyAcute coronary syndromeJPRN-UMIN000017205Kyorin University Hospital91